Indushekar Manjunatha

Indushekar Manjunatha

Auto-generated profile, based on publicly available information

Indushekar Manjunatha

Northeastern University, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2026
Verified
Book Chapter
Closed access
TVT. Vinciya
T. Vinciya
Praveen Javali RPraveen Javali R
Praveen Javali R
MSM. Shalini
M. Shalini
VPV. Premalatha
V. Premalatha
ATAman Suresh Tharayil
Aman Suresh Tharayil
IMIndushekar Manjunatha
Indushekar Manjunatha
This chapter per the authors examines the transformative impact of robotic systems on minimally invasive surgery (MIS), with a specific focus on ophthalmology, neurosurgery, and cardiovascular medicine. This chapter per the authors explores how robot-assisted systems address human limitations such as hand tremors and surgeon fatigue while enhancing precision through advanced imaging and motion control. The content details specialized applications, including retinal vein cannulation, deep brain stimulation, and endoscopic coronary bypass grafting. Furthermore, this chapter analyzes emerging innovations such as biohaptic intelligence, which restores the sense of touch to surgeons, and the potential of autonomous micro-robotics powered by smart materials and cybergenetics. Despite challenges regarding cost and technical complexity, this chapter per the authors concludes that the integration of artificial intelligence and digital twins will define the next generation of personalized surgical care.

17 October 2026
Verified
Book Chapter
Closed access
PSPavithraa Suresh
Pavithraa Suresh
ATAman Suresh Tharayil
Aman Suresh Tharayil
PKPriya Katiyar
Priya Katiyar
IMIndushekar Manjunatha
Indushekar Manjunatha
This chapter reviews biological biomarkers, routine laboratory indicators, and emerging artificial intelligence (AI) applications in vitiligo. While advances in pathogenesis have clarified genetic, oxidative, and autoimmune mechanisms, disease heterogeneity continues to limit the clinical utility of single candidate markers. To address these challenges, the text examines how integrating multi-omics datasets with machine learning algorithms can uncover robust predictive biomarker signatures. In addition, computational tools are highlighted for objective lesion detection, automated severity assessment (Auto-VASI), and longitudinal monitoring, as well as explainable AI approaches that enhance algorithmic transparency. Overcoming key barriers—including assay standardization, diverse population cohorts, and external validation—will be essential to translate these technologies into individualized clinical decision-making and advance precision dermatology.

14 August 2026
Verified
Book Chapter
Closed access
IMIndushekar Manjunatha
Indushekar Manjunatha
TATimothy Allen
Timothy Allen
SASreeja P. A.
Sreeja P. A.
The clinical translation of artificial intelligence-driven gene and cell therapies extends well beyond regulatory approval, depending on certified treatment-center infrastructure, integrated health workflows, and durable post-market evidence programs. This chapter, per the authors, examines how artificial intelligence tools are reshaping clinical implementation across four therapeutic platforms: CD19-directed CAR-T therapy in diffuse large B-cell lymphoma, AAV-based gene therapy in hemophilia, CRISPR-Cas9 editing in sickle cell disease and beta-thalassemia, and tumor-infiltrating lymphocyte therapy in metastatic melanoma. Grounded in recent quantitative real-world evidence, the text outlines a five-domain operational framework for AI-capable treatment sites. Additionally, it addresses the equity and global access challenges that will shape the field over the next decade, identifying persistent infrastructure, financing, and long-term follow-up obligations as defining operational themes.

17 October 2026
Verified
Book Chapter
Closed access
DPDhanalakshmi Perumal
Dhanalakshmi Perumal
GCGayathri K. C.
Gayathri K. C.
SSSsp
Ssp
SISist
Sist
YGYasmeen Imtiaz G.
Yasmeen Imtiaz G.
IMIndushekar Manjunatha
Indushekar Manjunatha
AI is on the verge of revolutionizing the clinical management of vitiligo from a visual assessment to precision medicine. In this chapter, the impact of AI and cutting-edge imaging techniques on disease classification and severity assessment through digitally enhanced Wood's lamp, AI-enhanced dermoscopy, and reflectance confocal microscopy is discussed. Automated morphometric analysis (Auto-VASI) can replace the traditional and subjectively performed clinical scoring, allowing clinicians to objectively monitor disease kinetics and anticipate therapeutic trajectories, while also incorporating digital biomarkers. The authors also discuss some critical translation issues, especially reducing algorithmic bias for a wide range of skin tones. In the end, the dermatologist with the human touch is able to provide mathematically optimized, personalized care with the help of AI.

17 October 2026
Verified
Book Chapter
Closed access
GKG. V. N. Kiranmayi
G. V. N. Kiranmayi
KRK. Ravishnakar
K. Ravishnakar
IMIndushekar Manjunatha
Indushekar Manjunatha
PKPriya Katiyar
Priya Katiyar
DBDarshan Huraliganganahalli Balaramegowda
Darshan Huraliganganahalli Balaramegowda
Vitiligo is an acquired disorder characterized by the autoimmune destruction of melanocytes, resulting in sharply demarcated depigmented patches. The purpose of this chapter, per the authors, is to synthesize the evolving therapeutic landscape of the disease. While physical morbidity is minimal, the psychosocial burden is substantial. Conventional treatments have relied on corticosteroids, calcineurin inhibitors, and phototherapy, but deeper mechanistic insight has enabled targeted immunotherapies. In particular, JAK–STAT pathway inhibition with agents like ruxolitinib halts interferon-gamma-driven melanocyte destruction to promote repigmentation. Phototherapy remains a mainstay for generalized disease, while surgical grafting and regenerative cell-based approaches benefit stable, refractory lesions. Ultimately, this chapter, per the authors, highlights the need for an integrated treatment strategy tailored to disease activity, anatomical site, and patient preferences.

14 August 2026
Verified
Book Chapter
Closed access
SASamad Ali
Samad Ali
AWAbdul Wahab
Abdul Wahab
IMIndushekar Manjunatha
Indushekar Manjunatha
SKShikha Khullar
Shikha Khullar
Mitochondrial disorders basically start with mtDNA mutations, and heteroplasmy kind of complicates everything. Artificial intelligence helps decode pathogenic variants, predicts the heteroplasmy thresholds, and figures out tissue energy deficits using multi-omics, sort of. Then AI sort of guides the design of mitochondria-targeted base editors, to boost specificity, and at the same time lessen off-target effects. Digital twin models simulate heteroplasmy shifts and support dose optimization before experimental validation. In addition, AI optimizes delivery vectors and safety frameworks, including the prediction of genomic rearrangements and unintended editing outcomes. In case studies covering myopathies, neurodegeneration, and cardiac disease, there's translational promise that feels pretty convincing. Overall, AI paired with mitochondrial engineering enables an intelligent approach for cellular energy restoration, even if it's a bit more complicated in practice.